raptor-platform
(4)
Dimi Kellari
Dimi Kellari is the co-founder and CEO of Neion Bio, a New York biotech using genetically engineered chicken eggs as biological factories to produce complex biologics like monoclonal antibodies at a fraction of the usual cost. An MIT-trained aerospace engineer who previously built autonomous-vehicle infrastructure at Cavnue and worked at Alphabet's X moonshot factory and McKinsey, Kellari co-founded Neion in 2024 with biologist Dr. Sam Levin around a single question: why, in 2024, are we still making our most important medicines in hamster cells? In June 2026 the company closed an oversubscribed $23 million Series A led by Caffeinated Capital.
Neion Bio
Neion Bio is a New York biotech company that genetically engineers chicken eggs into factories for complex biologic drugs. Its Raptor platform aims to make monoclonal antibodies and other glycosylated proteins at a fraction of the capital cost and carbon footprint of conventional cell-culture bioreactors. Founded in 2024 and emerged from stealth in March 2026, the company raised an oversubscribed $23 million Series A in June 2026 and signed an early multi-product biosimilar deal with a major global pharmaceutical company.
Pleno Inc.
Pleno Inc. is a San Diego multi-omic instrument company rebuilding the economics of biological target detection. Its RAPTOR platform, powered by proprietary Hypercoding technology borrowed from telecommunications signal processing, can detect up to 10,000 targets in a single sample at PCR-like speed and cost. Founded by serial entrepreneur Pieter van Rooyen, the company is moving from R&D into commercial launch with backing from Deerfield Management and Foresite Capital.
Vik Vaz
Vik Vaz is a physician-turned-executive who became CEO and President of San Diego multi-omics biotech Pleno Inc. in December 2024, arriving the same day the company closed a $25M Series B. Trained as a surgeon and interventional oncologist, he later ran strategy and companion diagnostics at Illumina and was a partner at both McKinsey and Boston Consulting Group. At Pleno he is commercializing the RAPTOR platform, which uses proprietary Hypercoding technology to detect DNA, RNA and protein targets in a single sample at high speed and low cost.